nodes	percent_of_prediction	percent_of_DWPC	metapath
Palonosetron—Infusion site pain—Capecitabine—esophageal cancer	0.0311	0.0548	CcSEcCtD
Palonosetron—HTR3A—vagus nerve—esophageal cancer	0.0187	0.714	CbGeAlD
Palonosetron—Peripheral sensory neuropathy—Capecitabine—esophageal cancer	0.0179	0.0315	CcSEcCtD
Palonosetron—Joint stiffness—Capecitabine—esophageal cancer	0.0169	0.0298	CcSEcCtD
Palonosetron—Sinus tachycardia—Capecitabine—esophageal cancer	0.0127	0.0223	CcSEcCtD
Palonosetron—Generalised oedema—Cisplatin—esophageal cancer	0.0116	0.0205	CcSEcCtD
Palonosetron—Prurigo—Capecitabine—esophageal cancer	0.0111	0.0195	CcSEcCtD
Palonosetron—Platelet count decreased—Capecitabine—esophageal cancer	0.00858	0.0151	CcSEcCtD
Palonosetron—Infection—Carboplatin—esophageal cancer	0.00837	0.0148	CcSEcCtD
Palonosetron—Pain—Carboplatin—esophageal cancer	0.0072	0.0127	CcSEcCtD
Palonosetron—Hiccups—Cisplatin—esophageal cancer	0.00693	0.0122	CcSEcCtD
Palonosetron—Hyperkalaemia—Cisplatin—esophageal cancer	0.00681	0.012	CcSEcCtD
Palonosetron—Body temperature increased—Carboplatin—esophageal cancer	0.00666	0.0117	CcSEcCtD
Palonosetron—Fluid retention—Cisplatin—esophageal cancer	0.00658	0.0116	CcSEcCtD
Palonosetron—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00635	0.0112	CcSEcCtD
Palonosetron—Extrasystoles—Capecitabine—esophageal cancer	0.00607	0.0107	CcSEcCtD
Palonosetron—Hypoxia—Methotrexate—esophageal cancer	0.00598	0.0105	CcSEcCtD
Palonosetron—Eye irritation—Capecitabine—esophageal cancer	0.00598	0.0105	CcSEcCtD
Palonosetron—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.00565	0.00997	CcSEcCtD
Palonosetron—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.00562	0.0099	CcSEcCtD
Palonosetron—Hypocalcaemia—Capecitabine—esophageal cancer	0.00558	0.00983	CcSEcCtD
Palonosetron—Cyanosis—Methotrexate—esophageal cancer	0.00537	0.00947	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.0052	0.00916	CcSEcCtD
Palonosetron—Hiccups—Capecitabine—esophageal cancer	0.00511	0.009	CcSEcCtD
Palonosetron—Injection site reaction—Capecitabine—esophageal cancer	0.00508	0.00895	CcSEcCtD
Palonosetron—Influenza like illness—Capecitabine—esophageal cancer	0.00496	0.00874	CcSEcCtD
Palonosetron—Fluid retention—Capecitabine—esophageal cancer	0.00485	0.00855	CcSEcCtD
Palonosetron—Hypokalaemia—Cisplatin—esophageal cancer	0.00458	0.00807	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00453	0.00798	CcSEcCtD
Palonosetron—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.00418	0.00737	CcSEcCtD
Palonosetron—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.00402	0.00708	CcSEcCtD
Palonosetron—Hot flush—Capecitabine—esophageal cancer	0.00396	0.00698	CcSEcCtD
Palonosetron—Menopausal symptoms—Capecitabine—esophageal cancer	0.00393	0.00692	CcSEcCtD
Palonosetron—Respiratory failure—Methotrexate—esophageal cancer	0.00387	0.00682	CcSEcCtD
Palonosetron—Pain in extremity—Capecitabine—esophageal cancer	0.00371	0.00653	CcSEcCtD
Palonosetron—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00366	0.00646	CcSEcCtD
Palonosetron—Bradycardia—Cisplatin—esophageal cancer	0.00354	0.00624	CcSEcCtD
Palonosetron—Urinary retention—Capecitabine—esophageal cancer	0.00352	0.00621	CcSEcCtD
Palonosetron—Urinary tract disorder—Cisplatin—esophageal cancer	0.00344	0.00606	CcSEcCtD
Palonosetron—Connective tissue disorder—Cisplatin—esophageal cancer	0.00342	0.00603	CcSEcCtD
Palonosetron—Urethral disorder—Cisplatin—esophageal cancer	0.00341	0.00601	CcSEcCtD
Palonosetron—Abdominal pain upper—Capecitabine—esophageal cancer	0.00339	0.00597	CcSEcCtD
Palonosetron—Hypokalaemia—Capecitabine—esophageal cancer	0.00337	0.00595	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00334	0.00588	CcSEcCtD
Palonosetron—Gastritis—Capecitabine—esophageal cancer	0.00328	0.00578	CcSEcCtD
Palonosetron—Eye disorder—Cisplatin—esophageal cancer	0.00325	0.00573	CcSEcCtD
Palonosetron—Tinnitus—Cisplatin—esophageal cancer	0.00324	0.00572	CcSEcCtD
Palonosetron—Cardiac disorder—Cisplatin—esophageal cancer	0.00323	0.00569	CcSEcCtD
Palonosetron—Abdominal distension—Capecitabine—esophageal cancer	0.00322	0.00568	CcSEcCtD
Palonosetron—Immune system disorder—Cisplatin—esophageal cancer	0.00314	0.00554	CcSEcCtD
Palonosetron—Mediastinal disorder—Cisplatin—esophageal cancer	0.00313	0.00553	CcSEcCtD
Palonosetron—Arrhythmia—Cisplatin—esophageal cancer	0.00311	0.00548	CcSEcCtD
Palonosetron—Alopecia—Cisplatin—esophageal cancer	0.00307	0.00542	CcSEcCtD
Palonosetron—Malnutrition—Cisplatin—esophageal cancer	0.00303	0.00534	CcSEcCtD
Palonosetron—Erythema—Cisplatin—esophageal cancer	0.00303	0.00534	CcSEcCtD
Palonosetron—Flatulence—Cisplatin—esophageal cancer	0.00298	0.00526	CcSEcCtD
Palonosetron—Hyperglycaemia—Capecitabine—esophageal cancer	0.00289	0.00509	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.00285	0.00503	CcSEcCtD
Palonosetron—Anaemia—Cisplatin—esophageal cancer	0.0028	0.00493	CcSEcCtD
Palonosetron—Hepatobiliary disease—Capecitabine—esophageal cancer	0.0027	0.00476	CcSEcCtD
Palonosetron—Epistaxis—Capecitabine—esophageal cancer	0.00269	0.00475	CcSEcCtD
Palonosetron—Convulsion—Cisplatin—esophageal cancer	0.00262	0.00462	CcSEcCtD
Palonosetron—Bradycardia—Capecitabine—esophageal cancer	0.00261	0.0046	CcSEcCtD
Palonosetron—Myalgia—Cisplatin—esophageal cancer	0.00258	0.00454	CcSEcCtD
Palonosetron—Anxiety—Cisplatin—esophageal cancer	0.00257	0.00453	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00256	0.00451	CcSEcCtD
Palonosetron—Discomfort—Cisplatin—esophageal cancer	0.00255	0.00449	CcSEcCtD
Palonosetron—Urinary tract disorder—Capecitabine—esophageal cancer	0.00253	0.00446	CcSEcCtD
Palonosetron—Connective tissue disorder—Capecitabine—esophageal cancer	0.00252	0.00444	CcSEcCtD
Palonosetron—Urethral disorder—Capecitabine—esophageal cancer	0.00251	0.00443	CcSEcCtD
Palonosetron—Anaphylactic shock—Cisplatin—esophageal cancer	0.00247	0.00436	CcSEcCtD
Palonosetron—Infection—Cisplatin—esophageal cancer	0.00246	0.00433	CcSEcCtD
Palonosetron—Nervous system disorder—Cisplatin—esophageal cancer	0.00242	0.00427	CcSEcCtD
Palonosetron—Tachycardia—Cisplatin—esophageal cancer	0.00241	0.00425	CcSEcCtD
Palonosetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00241	0.00593	CbGpPWpGaD
Palonosetron—CYP2D6—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.0024	0.00592	CbGpPWpGaD
Palonosetron—Skin disorder—Cisplatin—esophageal cancer	0.0024	0.00423	CcSEcCtD
Palonosetron—Eye disorder—Capecitabine—esophageal cancer	0.0024	0.00422	CcSEcCtD
Palonosetron—Tinnitus—Capecitabine—esophageal cancer	0.00239	0.00421	CcSEcCtD
Palonosetron—HTR3A—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00238	0.00587	CbGpPWpGaD
Palonosetron—Cardiac disorder—Capecitabine—esophageal cancer	0.00238	0.00419	CcSEcCtD
Palonosetron—Anorexia—Cisplatin—esophageal cancer	0.00236	0.00415	CcSEcCtD
Palonosetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00234	0.00576	CbGpPWpGaD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00233	0.00573	CbGpPWpGaD
Palonosetron—Angiopathy—Capecitabine—esophageal cancer	0.00233	0.0041	CcSEcCtD
Palonosetron—Immune system disorder—Capecitabine—esophageal cancer	0.00232	0.00408	CcSEcCtD
Palonosetron—Mediastinal disorder—Capecitabine—esophageal cancer	0.00231	0.00407	CcSEcCtD
Palonosetron—CYP2D6—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00231	0.00568	CbGpPWpGaD
Palonosetron—Hypotension—Cisplatin—esophageal cancer	0.00231	0.00407	CcSEcCtD
Palonosetron—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.0023	0.00567	CbGpPWpGaD
Palonosetron—Chills—Capecitabine—esophageal cancer	0.0023	0.00406	CcSEcCtD
Palonosetron—Arrhythmia—Capecitabine—esophageal cancer	0.00229	0.00404	CcSEcCtD
Palonosetron—Alopecia—Capecitabine—esophageal cancer	0.00227	0.00399	CcSEcCtD
Palonosetron—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00226	0.00555	CbGpPWpGaD
Palonosetron—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00225	0.00397	CcSEcCtD
Palonosetron—Mental disorder—Capecitabine—esophageal cancer	0.00225	0.00396	CcSEcCtD
Palonosetron—HTR3A—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00224	0.00551	CbGpPWpGaD
Palonosetron—CYP1A2—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.00224	0.0055	CbGpPWpGaD
Palonosetron—Erythema—Capecitabine—esophageal cancer	0.00223	0.00393	CcSEcCtD
Palonosetron—Malnutrition—Capecitabine—esophageal cancer	0.00223	0.00393	CcSEcCtD
Palonosetron—Paraesthesia—Cisplatin—esophageal cancer	0.00222	0.00391	CcSEcCtD
Palonosetron—Dyspnoea—Cisplatin—esophageal cancer	0.0022	0.00388	CcSEcCtD
Palonosetron—Flatulence—Capecitabine—esophageal cancer	0.0022	0.00388	CcSEcCtD
Palonosetron—Dysgeusia—Capecitabine—esophageal cancer	0.00219	0.00385	CcSEcCtD
Palonosetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00215	0.00529	CbGpPWpGaD
Palonosetron—Decreased appetite—Cisplatin—esophageal cancer	0.00215	0.00379	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00213	0.00376	CcSEcCtD
Palonosetron—HTR3A—digestive system—esophageal cancer	0.00213	0.0811	CbGeAlD
Palonosetron—HTR3A—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00212	0.00523	CbGpPWpGaD
Palonosetron—Pain—Cisplatin—esophageal cancer	0.00211	0.00373	CcSEcCtD
Palonosetron—Anaemia—Capecitabine—esophageal cancer	0.00206	0.00364	CcSEcCtD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00204	0.00502	CbGpPWpGaD
Palonosetron—CYP1A2—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.00204	0.00501	CbGpPWpGaD
Palonosetron—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00204	0.00501	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—esophageal cancer	0.00203	0.005	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—esophageal cancer	0.00203	0.005	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00203	0.00499	CbGpPWpGaD
Palonosetron—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00201	0.00354	CcSEcCtD
Palonosetron—Epistaxis—Methotrexate—esophageal cancer	0.00201	0.00354	CcSEcCtD
Palonosetron—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00198	0.00488	CbGpPWpGaD
Palonosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00198	0.00488	CbGpPWpGaD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00197	0.00485	CbGpPWpGaD
Palonosetron—CYP1A2—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00196	0.00481	CbGpPWpGaD
Palonosetron—Body temperature increased—Cisplatin—esophageal cancer	0.00195	0.00344	CcSEcCtD
Palonosetron—HTR3A—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00194	0.00478	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00194	0.00478	CbGpPWpGaD
Palonosetron—Hypertension—Capecitabine—esophageal cancer	0.00193	0.0034	CcSEcCtD
Palonosetron—Arthralgia—Capecitabine—esophageal cancer	0.0019	0.00335	CcSEcCtD
Palonosetron—Myalgia—Capecitabine—esophageal cancer	0.0019	0.00335	CcSEcCtD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.0019	0.00467	CbGpPWpGaD
Palonosetron—Anxiety—Capecitabine—esophageal cancer	0.00189	0.00334	CcSEcCtD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.00189	0.00466	CbGpPWpGaD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00189	0.00333	CcSEcCtD
Palonosetron—Urinary tract disorder—Methotrexate—esophageal cancer	0.00189	0.00332	CcSEcCtD
Palonosetron—Discomfort—Capecitabine—esophageal cancer	0.00188	0.00331	CcSEcCtD
Palonosetron—Urethral disorder—Methotrexate—esophageal cancer	0.00187	0.0033	CcSEcCtD
Palonosetron—Dry mouth—Capecitabine—esophageal cancer	0.00186	0.00328	CcSEcCtD
Palonosetron—CYP1A2—Tryptophan metabolism—ALDH2—esophageal cancer	0.00186	0.00457	CbGpPWpGaD
Palonosetron—Hypersensitivity—Cisplatin—esophageal cancer	0.00182	0.00321	CcSEcCtD
Palonosetron—Infection—Capecitabine—esophageal cancer	0.00181	0.00319	CcSEcCtD
Palonosetron—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.0018	0.00444	CbGpPWpGaD
Palonosetron—Shock—Capecitabine—esophageal cancer	0.00179	0.00316	CcSEcCtD
Palonosetron—Nervous system disorder—Capecitabine—esophageal cancer	0.00179	0.00315	CcSEcCtD
Palonosetron—Eye disorder—Methotrexate—esophageal cancer	0.00178	0.00314	CcSEcCtD
Palonosetron—Tinnitus—Methotrexate—esophageal cancer	0.00178	0.00314	CcSEcCtD
Palonosetron—Tachycardia—Capecitabine—esophageal cancer	0.00178	0.00313	CcSEcCtD
Palonosetron—HTR3A—lung—esophageal cancer	0.00178	0.0677	CbGeAlD
Palonosetron—Asthenia—Cisplatin—esophageal cancer	0.00177	0.00313	CcSEcCtD
Palonosetron—Cardiac disorder—Methotrexate—esophageal cancer	0.00177	0.00312	CcSEcCtD
Palonosetron—Skin disorder—Capecitabine—esophageal cancer	0.00177	0.00312	CcSEcCtD
Palonosetron—Anorexia—Capecitabine—esophageal cancer	0.00174	0.00306	CcSEcCtD
Palonosetron—Angiopathy—Methotrexate—esophageal cancer	0.00173	0.00305	CcSEcCtD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00173	0.00425	CbGpPWpGaD
Palonosetron—Immune system disorder—Methotrexate—esophageal cancer	0.00172	0.00304	CcSEcCtD
Palonosetron—Mediastinal disorder—Methotrexate—esophageal cancer	0.00172	0.00303	CcSEcCtD
Palonosetron—Chills—Methotrexate—esophageal cancer	0.00171	0.00302	CcSEcCtD
Palonosetron—Hypotension—Capecitabine—esophageal cancer	0.0017	0.003	CcSEcCtD
Palonosetron—Diarrhoea—Cisplatin—esophageal cancer	0.00169	0.00298	CcSEcCtD
Palonosetron—Alopecia—Methotrexate—esophageal cancer	0.00169	0.00297	CcSEcCtD
Palonosetron—Mental disorder—Methotrexate—esophageal cancer	0.00167	0.00295	CcSEcCtD
Palonosetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00167	0.0041	CbGpPWpGaD
Palonosetron—Malnutrition—Methotrexate—esophageal cancer	0.00166	0.00293	CcSEcCtD
Palonosetron—Erythema—Methotrexate—esophageal cancer	0.00166	0.00293	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00166	0.00293	CcSEcCtD
Palonosetron—Insomnia—Capecitabine—esophageal cancer	0.00165	0.0029	CcSEcCtD
Palonosetron—CYP2D6—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00165	0.00405	CbGpPWpGaD
Palonosetron—Paraesthesia—Capecitabine—esophageal cancer	0.00164	0.00288	CcSEcCtD
Palonosetron—Dysgeusia—Methotrexate—esophageal cancer	0.00163	0.00287	CcSEcCtD
Palonosetron—Dyspnoea—Capecitabine—esophageal cancer	0.00162	0.00286	CcSEcCtD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00161	0.00395	CbGpPWpGaD
Palonosetron—Dyspepsia—Capecitabine—esophageal cancer	0.0016	0.00283	CcSEcCtD
Palonosetron—Decreased appetite—Capecitabine—esophageal cancer	0.00158	0.00279	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00157	0.00277	CcSEcCtD
Palonosetron—Vomiting—Cisplatin—esophageal cancer	0.00157	0.00277	CcSEcCtD
Palonosetron—Fatigue—Capecitabine—esophageal cancer	0.00157	0.00277	CcSEcCtD
Palonosetron—Rash—Cisplatin—esophageal cancer	0.00156	0.00275	CcSEcCtD
Palonosetron—Constipation—Capecitabine—esophageal cancer	0.00156	0.00275	CcSEcCtD
Palonosetron—Pain—Capecitabine—esophageal cancer	0.00156	0.00275	CcSEcCtD
Palonosetron—Dermatitis—Cisplatin—esophageal cancer	0.00156	0.00274	CcSEcCtD
Palonosetron—CYP1A2—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.00155	0.00381	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.00155	0.00381	CbGpPWpGaD
Palonosetron—Anaemia—Methotrexate—esophageal cancer	0.00154	0.00271	CcSEcCtD
Palonosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00153	0.00376	CbGpPWpGaD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00152	0.00374	CbGpPWpGaD
Palonosetron—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00151	0.00372	CbGpPWpGaD
Palonosetron—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00149	0.00263	CcSEcCtD
Palonosetron—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00148	0.00363	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00147	0.00362	CbGpPWpGaD
Palonosetron—Nausea—Cisplatin—esophageal cancer	0.00147	0.00259	CcSEcCtD
Palonosetron—Abdominal pain—Capecitabine—esophageal cancer	0.00144	0.00254	CcSEcCtD
Palonosetron—Body temperature increased—Capecitabine—esophageal cancer	0.00144	0.00254	CcSEcCtD
Palonosetron—Convulsion—Methotrexate—esophageal cancer	0.00144	0.00254	CcSEcCtD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00144	0.00354	CbGpPWpGaD
Palonosetron—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.00143	0.00353	CbGpPWpGaD
Palonosetron—Myalgia—Methotrexate—esophageal cancer	0.00141	0.00249	CcSEcCtD
Palonosetron—Arthralgia—Methotrexate—esophageal cancer	0.00141	0.00249	CcSEcCtD
Palonosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00141	0.00348	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—esophageal cancer	0.00141	0.00347	CbGpPWpGaD
Palonosetron—CYP1A2—Tryptophan metabolism—CYP1B1—esophageal cancer	0.00141	0.00347	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—esophageal cancer	0.00141	0.00347	CbGpPWpGaD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.0014	0.00248	CcSEcCtD
Palonosetron—Discomfort—Methotrexate—esophageal cancer	0.0014	0.00246	CcSEcCtD
Palonosetron—CYP1A2—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00139	0.00343	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GSTO1—esophageal cancer	0.00136	0.00334	CbGpPWpGaD
Palonosetron—Anaphylactic shock—Methotrexate—esophageal cancer	0.00136	0.00239	CcSEcCtD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00135	0.00333	CbGpPWpGaD
Palonosetron—Infection—Methotrexate—esophageal cancer	0.00135	0.00237	CcSEcCtD
Palonosetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00134	0.00331	CbGpPWpGaD
Palonosetron—Hypersensitivity—Capecitabine—esophageal cancer	0.00134	0.00237	CcSEcCtD
Palonosetron—HTR3A—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00134	0.00329	CbGpPWpGaD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00133	0.00328	CbGpPWpGaD
Palonosetron—Nervous system disorder—Methotrexate—esophageal cancer	0.00133	0.00234	CcSEcCtD
Palonosetron—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00133	0.00326	CbGpPWpGaD
Palonosetron—CYP1A2—Tryptophan metabolism—CYP19A1—esophageal cancer	0.00132	0.00326	CbGpPWpGaD
Palonosetron—CYP1A2—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.00132	0.00324	CbGpPWpGaD
Palonosetron—Skin disorder—Methotrexate—esophageal cancer	0.00132	0.00232	CcSEcCtD
Palonosetron—Asthenia—Capecitabine—esophageal cancer	0.00131	0.0023	CcSEcCtD
Palonosetron—Anorexia—Methotrexate—esophageal cancer	0.00129	0.00228	CcSEcCtD
Palonosetron—Pruritus—Capecitabine—esophageal cancer	0.00129	0.00227	CcSEcCtD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00128	0.00315	CbGpPWpGaD
Palonosetron—Hypotension—Methotrexate—esophageal cancer	0.00127	0.00223	CcSEcCtD
Palonosetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00126	0.00311	CbGpPWpGaD
Palonosetron—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00125	0.00307	CbGpPWpGaD
Palonosetron—Diarrhoea—Capecitabine—esophageal cancer	0.00125	0.0022	CcSEcCtD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00124	0.00305	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—ADH7—esophageal cancer	0.00124	0.00304	CbGpPWpGaD
Palonosetron—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00124	0.00218	CcSEcCtD
Palonosetron—Insomnia—Methotrexate—esophageal cancer	0.00123	0.00216	CcSEcCtD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00122	0.003	CbGpPWpGaD
Palonosetron—Paraesthesia—Methotrexate—esophageal cancer	0.00122	0.00215	CcSEcCtD
Palonosetron—Dyspnoea—Methotrexate—esophageal cancer	0.00121	0.00213	CcSEcCtD
Palonosetron—Somnolence—Methotrexate—esophageal cancer	0.00121	0.00213	CcSEcCtD
Palonosetron—Dizziness—Capecitabine—esophageal cancer	0.0012	0.00212	CcSEcCtD
Palonosetron—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.0012	0.00294	CbGpPWpGaD
Palonosetron—Dyspepsia—Methotrexate—esophageal cancer	0.00119	0.0021	CcSEcCtD
Palonosetron—Decreased appetite—Methotrexate—esophageal cancer	0.00118	0.00208	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00117	0.00206	CcSEcCtD
Palonosetron—Fatigue—Methotrexate—esophageal cancer	0.00117	0.00206	CcSEcCtD
Palonosetron—Pain—Methotrexate—esophageal cancer	0.00116	0.00204	CcSEcCtD
Palonosetron—Vomiting—Capecitabine—esophageal cancer	0.00116	0.00204	CcSEcCtD
Palonosetron—Rash—Capecitabine—esophageal cancer	0.00115	0.00202	CcSEcCtD
Palonosetron—Dermatitis—Capecitabine—esophageal cancer	0.00115	0.00202	CcSEcCtD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00115	0.00282	CbGpPWpGaD
Palonosetron—Headache—Capecitabine—esophageal cancer	0.00114	0.00201	CcSEcCtD
Palonosetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00114	0.0028	CbGpPWpGaD
Palonosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00114	0.0028	CbGpPWpGaD
Palonosetron—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00112	0.00276	CbGpPWpGaD
Palonosetron—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00111	0.00195	CcSEcCtD
Palonosetron—CYP1A2—digestive system—esophageal cancer	0.0011	0.0419	CbGeAlD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—esophageal cancer	0.0011	0.0027	CbGpPWpGaD
Palonosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00109	0.00268	CbGpPWpGaD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00109	0.00268	CbGpPWpGaD
Palonosetron—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.00109	0.00267	CbGpPWpGaD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00109	0.00267	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—ADH1B—esophageal cancer	0.00108	0.00267	CbGpPWpGaD
Palonosetron—Nausea—Capecitabine—esophageal cancer	0.00108	0.00191	CcSEcCtD
Palonosetron—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00108	0.00265	CbGpPWpGaD
Palonosetron—Body temperature increased—Methotrexate—esophageal cancer	0.00107	0.00189	CcSEcCtD
Palonosetron—Abdominal pain—Methotrexate—esophageal cancer	0.00107	0.00189	CcSEcCtD
Palonosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00107	0.00263	CbGpPWpGaD
Palonosetron—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00106	0.0026	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.00105	0.00259	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GSTT1—esophageal cancer	0.00105	0.00259	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—ADH7—esophageal cancer	0.00105	0.00258	CbGpPWpGaD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00102	0.00252	CbGpPWpGaD
Palonosetron—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.00102	0.00251	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.00101	0.00248	CbGpPWpGaD
Palonosetron—Hypersensitivity—Methotrexate—esophageal cancer	0.000999	0.00176	CcSEcCtD
Palonosetron—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000994	0.00245	CbGpPWpGaD
Palonosetron—Asthenia—Methotrexate—esophageal cancer	0.000973	0.00172	CcSEcCtD
Palonosetron—Pruritus—Methotrexate—esophageal cancer	0.000959	0.00169	CcSEcCtD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00094	0.00231	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.000937	0.00231	CbGpPWpGaD
Palonosetron—Diarrhoea—Methotrexate—esophageal cancer	0.000928	0.00164	CcSEcCtD
Palonosetron—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.000924	0.00227	CbGpPWpGaD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000923	0.00227	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—ADH1B—esophageal cancer	0.000918	0.00226	CbGpPWpGaD
Palonosetron—CYP1A2—lung—esophageal cancer	0.000917	0.035	CbGeAlD
Palonosetron—Dizziness—Methotrexate—esophageal cancer	0.000897	0.00158	CcSEcCtD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000884	0.00217	CbGpPWpGaD
Palonosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000879	0.00216	CbGpPWpGaD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000868	0.00214	CbGpPWpGaD
Palonosetron—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000867	0.00213	CbGpPWpGaD
Palonosetron—Vomiting—Methotrexate—esophageal cancer	0.000862	0.00152	CcSEcCtD
Palonosetron—Rash—Methotrexate—esophageal cancer	0.000855	0.00151	CcSEcCtD
Palonosetron—Dermatitis—Methotrexate—esophageal cancer	0.000854	0.00151	CcSEcCtD
Palonosetron—CYP1A2—Biological oxidations—CYP26A1—esophageal cancer	0.000854	0.0021	CbGpPWpGaD
Palonosetron—Headache—Methotrexate—esophageal cancer	0.00085	0.0015	CcSEcCtD
Palonosetron—CYP1A2—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000842	0.00207	CbGpPWpGaD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000838	0.00206	CbGpPWpGaD
Palonosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000826	0.00203	CbGpPWpGaD
Palonosetron—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000815	0.00201	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000814	0.002	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000808	0.00199	CbGpPWpGaD
Palonosetron—Nausea—Methotrexate—esophageal cancer	0.000806	0.00142	CcSEcCtD
Palonosetron—CYP3A4—digestive system—esophageal cancer	0.000795	0.0303	CbGeAlD
Palonosetron—CYP1A2—Biological oxidations—GSTO1—esophageal cancer	0.000794	0.00195	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—GSTO1—esophageal cancer	0.000783	0.00193	CbGpPWpGaD
Palonosetron—CYP2D6—digestive system—esophageal cancer	0.000782	0.0298	CbGeAlD
Palonosetron—HTR3A—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000782	0.00192	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000772	0.0019	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.000764	0.00188	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.000727	0.00179	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.000718	0.00177	CbGpPWpGaD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000712	0.00175	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000709	0.00174	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.000681	0.00167	CbGpPWpGaD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00067	0.00165	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000659	0.00162	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00065	0.0016	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—ALDH2—esophageal cancer	0.000647	0.00159	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	0.000635	0.00156	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTT1—esophageal cancer	0.000615	0.00151	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000613	0.00151	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—CYP2A6—esophageal cancer	0.000608	0.0015	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000604	0.00149	CbGpPWpGaD
Palonosetron—CYP1A2—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000594	0.00146	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000579	0.00142	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—PTGS1—esophageal cancer	0.000577	0.00142	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000571	0.0014	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000555	0.00137	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000544	0.00134	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000537	0.00132	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000528	0.0013	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.000528	0.0013	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000522	0.00129	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000499	0.00123	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	0.00049	0.00121	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000484	0.00119	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000475	0.00117	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000473	0.00116	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.00047	0.00116	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	0.000461	0.00113	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.00046	0.00113	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000455	0.00112	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.00045	0.00111	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.00045	0.00111	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000445	0.0011	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000378	0.000931	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000373	0.000918	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000356	0.000875	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000351	0.000863	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.00032	0.000786	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000292	0.000719	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000292	0.000719	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000279	0.000686	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CA1—esophageal cancer	0.000249	0.000612	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000249	0.000612	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SLC52A3—esophageal cancer	0.000248	0.00061	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—BLVRB—esophageal cancer	0.000248	0.00061	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CA2—esophageal cancer	0.000227	0.00056	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000221	0.000545	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000211	0.00052	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000211	0.00052	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CA1—esophageal cancer	0.000211	0.000518	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SLC10A2—esophageal cancer	0.000211	0.000518	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CA2—esophageal cancer	0.000193	0.000474	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000191	0.00047	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000191	0.00047	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000188	0.000463	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000185	0.000456	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PLCE1—esophageal cancer	0.000179	0.000441	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ADH7—esophageal cancer	0.000179	0.000441	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000177	0.000436	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000177	0.000436	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000172	0.000424	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000168	0.000413	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000163	0.0004	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CA1—esophageal cancer	0.000163	0.0004	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—TPI1—esophageal cancer	0.00016	0.000394	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.00016	0.000394	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ADH1B—esophageal cancer	0.000157	0.000386	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000154	0.000378	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—TYMP—esophageal cancer	0.00015	0.000369	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CA2—esophageal cancer	0.000149	0.000366	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000148	0.000364	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000147	0.000361	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP26A1—esophageal cancer	0.000146	0.000359	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ALOX15—esophageal cancer	0.000142	0.00035	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GNG7—esophageal cancer	0.000139	0.000343	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ADH7—esophageal cancer	0.000138	0.00034	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.000138	0.00034	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—TPI1—esophageal cancer	0.000136	0.000334	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTO1—esophageal cancer	0.000136	0.000334	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ALDH2—esophageal cancer	0.000131	0.000321	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ALDOB—esophageal cancer	0.00013	0.00032	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GAPDH—esophageal cancer	0.000125	0.000308	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTT1—esophageal cancer	0.000124	0.000306	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CRABP1—esophageal cancer	0.000124	0.000305	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP2A6—esophageal cancer	0.000123	0.000302	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ADH1B—esophageal cancer	0.000121	0.000298	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GNG7—esophageal cancer	0.000118	0.000291	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ENO1—esophageal cancer	0.000116	0.000286	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PTGS1—esophageal cancer	0.000116	0.000286	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—TYMP—esophageal cancer	0.000116	0.000285	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PSME1—esophageal cancer	0.000115	0.000282	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PSME2—esophageal cancer	0.000115	0.000282	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP26A1—esophageal cancer	0.000113	0.000277	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ALDH2—esophageal cancer	0.000111	0.000272	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ALOX15—esophageal cancer	0.00011	0.00027	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTT1—esophageal cancer	0.000105	0.000259	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—TPI1—esophageal cancer	0.000105	0.000258	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTO1—esophageal cancer	0.000105	0.000258	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP2A6—esophageal cancer	0.000104	0.000256	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000104	0.000255	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ALDOB—esophageal cancer	0.0001	0.000247	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP1B1—esophageal cancer	9.9e-05	0.000244	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ENO1—esophageal cancer	9.86e-05	0.000243	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PTGS1—esophageal cancer	9.86e-05	0.000243	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PSME2—esophageal cancer	9.72e-05	0.000239	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PSME1—esophageal cancer	9.72e-05	0.000239	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GAPDH—esophageal cancer	9.67e-05	0.000238	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CRABP1—esophageal cancer	9.58e-05	0.000236	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP19A1—esophageal cancer	9.31e-05	0.000229	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GNG7—esophageal cancer	9.11e-05	0.000224	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ALDH2—esophageal cancer	8.54e-05	0.00021	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—HMOX1—esophageal cancer	8.49e-05	0.000209	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.49e-05	0.000209	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP1B1—esophageal cancer	8.39e-05	0.000206	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ABCB1—esophageal cancer	8.15e-05	0.000201	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTT1—esophageal cancer	8.12e-05	0.0002	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP2A6—esophageal cancer	8.03e-05	0.000198	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP19A1—esophageal cancer	7.88e-05	0.000194	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ENO1—esophageal cancer	7.61e-05	0.000187	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PTGS1—esophageal cancer	7.61e-05	0.000187	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PSME1—esophageal cancer	7.5e-05	0.000185	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PSME2—esophageal cancer	7.5e-05	0.000185	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—HMOX1—esophageal cancer	7.2e-05	0.000177	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.06e-05	0.000174	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ABCB1—esophageal cancer	6.91e-05	0.00017	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP1B1—esophageal cancer	6.47e-05	0.000159	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP19A1—esophageal cancer	6.09e-05	0.00015	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—HMOX1—esophageal cancer	5.55e-05	0.000137	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CREBBP—esophageal cancer	5.45e-05	0.000134	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ABCB1—esophageal cancer	5.33e-05	0.000131	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.22e-05	0.000128	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NOS3—esophageal cancer	4.88e-05	0.00012	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CREBBP—esophageal cancer	4.62e-05	0.000114	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PTGS2—esophageal cancer	4.46e-05	0.00011	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NOS3—esophageal cancer	4.13e-05	0.000102	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PTGS2—esophageal cancer	3.78e-05	9.3e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—EP300—esophageal cancer	3.71e-05	9.13e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.56e-05	8.76e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NOS3—esophageal cancer	3.19e-05	7.85e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—EP300—esophageal cancer	3.14e-05	7.73e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.92e-05	7.18e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CA—esophageal cancer	2.74e-05	6.75e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—EP300—esophageal cancer	2.43e-05	5.97e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CA—esophageal cancer	2.33e-05	5.72e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.79e-05	4.42e-05	CbGpPWpGaD
